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and matched for age, gender and geographic location. The index date was defined 
as the date of the first AD diagnosis or the first script for AD medication whichever 
comes first. Prevalence of diseases and treatment exposures in the years preceding 
the index date were analyzed according to the occurrence of diseases (ICD-9 codes) 
and medication utilization (AHFS codification) between AD patients and the control 
group. Results: Data were obtained for a random sample of 34,086 AD patients 
(mean age of 78.5 years [SD= 8.0], 65.2% females). A higher proportion of patients 
had a diagnosis of organic psychotic conditions (49.6% vs. 9.2%, p< 0.001), other 
psychoses (21.9% vs. 8.6%, p< 0.001) and neurotic disorders, personality disorders 
and other nonpsychotic mental disorders (69.1% vs. 55.4%, p< 0.001) in the AD group 
compared to the control group. Furthermore, a greater number of patients used psy-
chotropic drugs (53.5% vs. 35.9%, p< 0.001) and anxiolytics, sedatives and hypnotics 
(70.3% vs. 65.9%, p< 0.001) in the AD group than in the control group. ConClusions: 
Comorbidities’ frequency was higher in AD patients for several diseases and treat-
ments, particularly for mental disorders-related diagnoses and medications.
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objeCtives: To estimate the efficacy of fingolimod versus placebo on confirmed 
disability progression (CDP) and on time to severe disability health states in 
patients with relapsing–remitting multiple sclerosis (RRMS) failing prior treat-
ment. Methods: Patients failing prior treatment were defined as: 1) ≥ 1 relapse 
in the previous year and either ≥ 1 gadolinium-enhancing T1 lesion or a T2 lesion 
count ≥ 9 at baseline, or 2) equal or more relapses in the year prior to baseline 
compared with the previous year. Hazard ratios (HR) for 3-month and 6-month CDP, 
measured using Expanded Disability Status Scale (EDSS) scores, were estimated 
using Cox proportional hazards models. Both per-protocol definitions of CDP and 
revised definitions used in other trials were analysed. Time from EDSS score 0 to 
scores of 4 or 6 and to conversion to secondary progressive MS (SPMS) were esti-
mated by fitting a multi-state Markov Transition model to individual patient data 
from the pooled FREEDOMS placebo groups (HRs accounted for treatment effects) 
and the London Ontario cohort (SPMS and RRMS–SPMS transitions). Results: 
Using both definitions of treatment failure, fingolimod reduced the risk of 3-month 
CDP (per-protocol) by 35% (definition 1: HR: 0.65; p< 0.05) and 34% (definition 2: 
HR: 0.66; p< 0.05) versus placebo. The corresponding HRs for 6-month CDP were 
0.61 (p= 0.06) and 0.60 (p< 0.05). HRs were generally lower using the revised CDP 
definition. The Markov Transition model, assuming a 40% reduction, estimated 
that fingolimod delays the median time to EDSS 4 (2.2 years, 61% increase), EDSS 
6 (3.3 years, 52% increase) and SPMS (4.5 years, 62% increase) compared with pla-
cebo. ConClusions: Fingolimod is highly efficacious in delaying CDP in patients 
failing prior treatment, and our modeling approach suggests that this translates 
into a meaningful delay in time to severe disability health states.
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comPariNg tHE Efficacy of first aND sEcoND gENEratioN DisEasE-
moDifyiNg tHEraPiEs for rElaPsiNg-rEmittiNg multiPlE sclErosis:  
a NEtwork mEta-aNalysis
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objeCtives: As the number of available disease-modifying therapies (DMT) for 
relapsing-remitting multiple sclerosis (RRMS) expands, consideration of all evidence 
on comparative efficacy of newer second generation therapies with established 
first generation therapies is required to inform clinical care and health policy. This 
network meta-analysis (NMA) estimates the relative efficacy of DMT in reducing 
relapses and slowing short-term progression of disability in RRMS. Methods: A 
systematic review of RCTs of interferon-beta, glatiramer acetate (first generation 
DMTs), natalizumab, alemtuzumab, fingolimod, teriflunomide, laquinimod, and 
BG-12 (second generation DMTs) compared with each other or with placebo for the 
treatment of RRMS, identified 20 eligible RCTs (n= 14610). A random-effects NMA 
model was used to calculate relative annualized relapse rate (ARR) and hazard 
ratio (HR) of short-term disability progression. Results: Statistically significant 
reductions in ARR versus placebo, between 24% - 69% for second generation DMTs 
and 16% - 33% for first generation DMTs were found. Alemtuzumab, natalizumab, 
fingolimod, and BG-12 were significantly more efficacious than other DMTs in 
reducing ARR. There was greater uncertainty associated with DMT efficacy in reduc-
ing short-term disability progression. Significant improvements over placebo in 
reducing short-term disability progression were restricted to second generation 
DMTs alemtuzumab, natalizumab, fingolimod, laquinimod, BG-12, and terifluno-
mide 14mg (HR 0.27 - 0.54). No statistically significant improvements in short-term 
disability progression were exhibited by first generation DMTs and teriflunomide 
7mg. ConClusions: The growing number of innovative second generation DMTs 
offers the potential of therapeutic advances in reducing relapse rates in RRMS, with 
less certain benefits on short-term disability progression. Despite these potential 
advantages, the relative position of second generation DMTs on the RRMS treatment 
landscape remains to be defined, due to potentially serious side effects, limited 
long-term safety data and their high cost.
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disagree that innovation in health care is worthwhile; the tremendous technological 
success in pharmacological treatment of HIV patients is a case in point. On the other 
hand, a relatively large number of “me-too” entries in the pharmaceutical market 
and the diminishing productivity of R&D sector call for robust methodologies, which 
could distinguish high-value, breakthrough products. Sensitivity analyses of cost-
effectiveness studies should be made pivotal in decision-making process in order 
to ensure efficient diffusion of innovation.
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miNimisatioN mEasurEs for mEDiciNal ProDucts
Prieto L., Hidalgo-Simon A., Arlett P.
European Medicines Agency, London, UK
The introduction of the risk management plan (RMP) has ensured greater proactivity 
to the pharmacovigilance and post-authorisation benefit risk assessment of human 
medicines. An RMP may include risk minimisation measures (RMM), public health 
interventions intended to prevent the occurrence, or reduce the impact of adverse 
drug reactions associated with the exposure to a drug. The new EU legislation on 
pharmacovigilance explicitly requires the active monitoring of the outcome of RMM, 
placing obligations on regulators and industry for this purpose. In this respect, the 
European Medicines Agency’s good pharmacovigilance practices module dedicated 
to the practical implementation of the legislation on the evaluation of the effective-
ness of RMM foresees a dual evidence approach. This approach builds on the assess-
ment of two distinct levels of evidence: the actual implementation of the RMM, and 
the attainment of its final objective(s). The approach requires research encompass-
ing analysis of implementation (process indicators), and traditional epidemiological 
research addressing the attainment (final outcome indicators) of RMM. Surveys 
are usually involved in the assessment of process indicators, in particular when 
RMM imply the provision of educational information to health care professionals 
(HCP) and the surveys are intended to measure what the HCP have learned. This 
paper aims to conceptualise the construction of surveys designed for the analysis of 
implementation of RMM. Such surveys should be developed following the principles 
of content validation. This requires a body of relevant questions (items), the sample 
population to which it will be administered, and a test plan. The test plan includes 
the type of items to be used, the number of items, the length of administration, 
how it is to be administered, and how it is to be scored and analysed in terms of 
item difficulty and discrimination. The paper concludes with a checklist to assist 
stakeholders in designing surveys for RMM assessment purposes.
DisEasE-sPEcific stuDiEs
NEurological DisorDErs – clinical outcomes studies
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objeCtives: To summarize literature on the burden of epilepsy in tuberous sclero-
sis complex (TSC); TSC is a genetic disease characterized by behavioral disorders, 
benign tumors in multiple organs, and neurological manifestations including epi-
lepsy. Methods: A systematic search of keywords for TSC and burden of illness 
was conducted in MEDLINE- and EMBASE-indexed publications from 5/2000-1/2013, 
and non-indexed materials. Results: In total, 83 articles on TSC-associated epi-
lepsy were included. Up to 93% of TSC patients have epilepsy, with severe forms 
more common than in non-TSC epilepsy patients (infantile spasms, 35-57% vs. 9%; 
generalized tonic-clonic or grand mal seizures, 37% vs. 7%; complex focal seizures, 
87% vs. 33%). Seizure onset is early (median age: 7 months, 82% by age 3). TSC2 
gene mutations and cortical tubers, common brain malformations in TSC, are risk 
factors for early onset and greater severity of seizures. TSC-epilepsy patients have 
significant disabilities, including high rates of autism spectrum disorders (13-30%) 
and cognitive impairment/delay (62-80%). Although data are not available on long-
term outcomes, early seizure control may reduce cognitive impairment and autism 
symptoms. Vigabatrin is a first-line treatment option for TSC-associated infantile 
spasms and focal seizures in infants, but poses a risk of serious retinal toxicity. 
Other anti-epileptic drugs are available as second-line options; most patients still 
require polytherapy, and 62% have refractory epilepsy that can necessitate surgery. 
With high rates of medication use, hospitalizations, and surgeries, TSC-epilepsy 
patients may consume substantial health care resources, particularly during the 
first 5 years post-diagnosis. Longitudinal trends in resource use, direct and indirect 
costs, and treatment patterns for TSC-epilepsy are largely absent from the litera-
ture. ConClusions: TSC-epilepsy is common and may be severe, with presenta-
tion early in childhood and long-term morbidity. True disease burden to patients, 
caregivers, and payers remains unknown given substantial data gaps in longitudinal 
clinical outcomes, treatment patterns, and costs.
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objeCtives: To identify potential determinants of Alzheimer’s disease (AD) by ana-
lyzing past medical history in terms of previous diseases or treatment exposures 
of patients with AD compared to patients without the disease, using the Quebec 
provincial drug reimbursement program database (RAMQ). Methods: This ret-
rospective study included patients covered by the RAMQ who had at least one 
diagnosis of AD (ICD-9 code 3310) or have received at least one script for an AD 
medication (donepezil, rivastigmine, galantamine or memantine) from January, 1985 
to December, 2011. A control group of patients without AD was created on a 1:1 ratio 
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on naïve and exposed populations was available for colistin and colistin-P, respec-
tively. ConClusions: By conducting an alternative approach where the naïve and 
exposed arms were considered separate treatment-by-population groups, the full 
evidence base could be evaluated, including the data for the dry-powder colis-
timethate sodium inhaler. This will provide relevant information to support clinical 
decision making in CF.
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objeCtives: To gather data on clinical effectiveness of lacosamide add-on ther-
apy to standard antiepileptic drugs (AEDs) in the Czech Republic. These data were 
intended as inputs for a cost-effectiveness analysis. Methods: A retrospective 
multicenter (n= 40) data collection of patients with epilepsy treated with lacosamide 
for 6 months in clinical practice was performed. Information on the number of sei-
zures and concomitant AEDs before and after lacosamide treatment was observed. 
In this analysis patients reporting at least a 50% reduction in seizure number 3 
months after lacosamide treatment were considered responders. Adverse events 
reported after initiating lacosamide treatment were collected. Results: In total, 
data from 409 patients were collected, 403 had complete data that were analyzed. 
Mean (SD) age was 40.4 (±14.2) years and the mean (SD) time since diagnosis 18.7 
(±12.8) years. In 91% of patients lacosamide treatment was initiated because of 
resistance to previous AEDs. Most patients suffered from partial (44.2%), second-
ary generalized (20.1%) or both (34.0%) types of seizures, or other (1.7%). Following 
lacosamide administration the mean (median) number of seizures decreased from 
baseline of 40.3 (12.0) to 25.9 (7.0) (per 3 months). Median (mean) number of sei-
zure reduction was equal to 41% (30%), and 45% were responders. Adverse events 
occurred in 79 pts (19.6%), with somnolence (6.2%) and dizziness (5.5%) most fre-
quently reported. During lacosamide administration, a decrease in concomitant 
AEDs number was observed. The mean number per patient decreased from 2.2 to 
1.7, as did concomitant AEDs used before and after lacosamide administration: 
levetiracetam (39% vs. 33%), lamotrigine (38% vs. 32%), carbamazepine (34% vs. 
29%), valproate (33% vs. 28%) and zonisamide (17% vs. 8%). ConClusions: Results 
confirm the effectiveness of lacosamide in the reduction of seizure frequency in 
clinical practice. In addition, findings suggest that adding lacosamide may lead to 
a reduced use of other concomitant AEDs.
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objeCtives: To analyse the cost of different anti-migraine products to determine 
price differences and the impact of generic prescribing. Methods: A retrospective 
drug utilisation study was conducted on South African medical insurance claims 
data for 2011. No clinical information was available. Results: A total of 797 patients 
received 1583 anti-migraine products during 2011. The majority of patients (70.14%) 
were females and 47.05% of patients were between 30 and 49 years old. Only 13.96% 
of patients claimed their anti-migraine products from the chronic plan of their 
medical insurance schemes. The average age of patients was 41.61 (SD= 14.91) years, 
with females on average slightly older than males (41.89 years vs. 40.96 years). 
Clonidine was the most frequently prescribed active ingredient (accounting for 
49.21% of the number of prescriptions, yet only for 25.70% of the amount claimed for 
anti-migraine products). Triptans (selective serotonin (5-HT1B/1D)-receptor agonists) 
accounted for 27.98% of all anti-migraine prescriptions, but accounted for 45.92% 
of cost. Five different triptans were prescribed. The average cost per sumatriptan 
prescription was the lowest (R177.64) of all the triptans. Sumatriptan was the only 
triptan with generic equivalents. Rizatriptan was the most often prescribed triptan, 
accounting for 18.51% of prescribing frequency and 29.15% of the amount claimed. 
Tablets and wafers were the preferred dosage forms. Only 0.32% of prescriptions 
were for triptan nasal sprays and they were on average the most expensive dos-
age form prescribed (R428.82 per prescription). ConClusions: The results of this 
study were in agreement with the findings of previous South African studies. The 
cost saving implications of generic prescribing were clear in this study. Migraine is 
an expensive condition to treat and is also affecting the economically active sec-
tor of the population. Studies investigating the economic impact of migraine will 
therefore yield valuable results.
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objeCtives: Despite the lack of evidence-based efficacy of cerebroprotective drugs, 
one-third of Europe’s population uses of these drugs (WHO statistics). The pur-
pose of the study - to research the dynamics of cerebroprotectors consumption in 
Ukraine. Methods: Determination of cerebroprotectors consumption by means of 
frequency analysis, ATC/DDD-methodology during 6 months in 2012 in Ukraine. The 
consumption of cerebroprotective drugs in money term does not give a true picture 
about the volume of pharmacotherapy using these drugs, that is why ATC/DDD-
methodology was used. As a unit of consumption DDD and PDD were used. Results: 
A comparison of outpatient and inpatient cerebroprotective drugs consumption 
during 6 months in a neurological hospital and in a drugstore in Kharkov, it was 
found, that 58 trade names (TN) of drugs in the amount of $ 28218 (the rate of $ 1: 
8,16 UAH on 1.10.12), in the hospital 17 TNs were used in the amount of $1518. It is 
shown, that the inpatient consumption of cerebroprotectors is much higher, than 
outpatient consumption, for example, vincamine - 2,32 DDDs/100 patients and 1,66 
DDDs/100 bed–days; piracetam - 2,59 DDDs /100 patients and 0, 15 DDDs/100 bed-
objeCtives: To assess the effects of early psychosocial intervention on delaying the 
institutionalization of patients with mild Alzheimer’s disease (AD) and on caregiv-
ers’ health-related quality of life (HRQOL). Methods: Totally, 240 patient-caregiver 
dyads were recruited to a pragmatic, controlled, and randomized (1:2) clinical trial 
in 3 hospital districts in Finland between 2002-2006. A primary outcome measure 
was the intervention’s impact on cumulative risk of institutionalization over 36 
months of follow up. In the analysis of the primary outcome, Fine & Gray’s (1999) 
proportional subhazards (sHR) model was applied to adjust the impact of compet-
ing risk (i.e., death). Main secondary outcome measures were caregivers’ global 
burden (measured by Global Health Questionnaire GHQ) and HRQOL measured by 
the 15D. The secondary outcomes were analyzed using generalized linear mixed 
models (GLMM) with hierarchical structure to account for repeated measures and 
possible clustering by the hospital district. Results: After 36 months of follow 
up, cumulative competing risk adjusted incidence of institutionalization rates 
(95% CI) were 21.2% (12.5% – 29.9%) and 16.1% (10.3% - 21.9%) in the intervention 
and usual care groups, respectively. Age and sex adjusted sHR was 1.37 (95%CI 
0.75 – 2.52). No statistical significant differences in the secondary outcomes were 
found. ConClusions: The early psychosocial intervention for patients with mild 
AD and their caregivers did not delay time to nursing home placement. The results 
of the present study are consistent with a recently published study (Waldorff et al. 
2012 BMJ) reporting no effect of semi-tailored intervention for patients with mild 
AD and their caregivers. Even if the present study did not manage to show differ-
ences between the study groups, it provides the valuable longitudinal dataset for 
studying long-term disease progression (in terms of correlated cognitive, behavioral, 
and functional disabilities) and its economic and quality of life consequences for 
patients with AD and their caregivers.
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objeCtives: To estimate the comparative efficacy of oral therapies (fingolimod, dime-
thyl fumarate [DMF] and teriflunomide) in delaying progression to disability health 
states in patients with relapsing–remitting multiple sclerosis (RRMS). Methods: Cox 
proportional hazards regression models were used to analyse 6-month confirmed 
disability progression (CDP; based on Expanded Disability Status Scale [EDSS] scores) 
in the pooled fingolimod FREEDOMS trials. Initial models were constructed with eight 
baseline covariates as main and treatment-interaction effects and final models with 
the most predictive covariates were selected using a stepwise algorithm. Models 
predicted hazard ratios (HRs) for 6-month CDP for fingolimod 0.5mg versus placebo 
for average TEMSO (teriflunomide trial) and pooled DEFINE/CONFIRM (DMF trials) 
patients. Time from EDSS score 0 to scores of 4 or 6 and to conversion to secondary 
progressive multiple sclerosis (SPMS) were estimated by fitting a multi-state Markov 
Transition model to individual patient data from the pooled FREEDOMS placebo 
groups (HRs accounted for treatment effects) and the London Ontario cohort (SPMS 
and RRMS–SPMS transitions). Results: Without covariate adjustment, the HR for 
CDP for fingolimod versus placebo in the pooled FREEDOMS trials was numerically 
lower (i.e. fingolimod more efficacious) than that for DMF twice daily versus placebo 
in DEFINE/CONFIRM (0.62 vs. 0.71). In adjusted comparisons, the predicted HR for 
fingolimod versus placebo in the DEFINE/CONFIRM population was lower than in the 
FREEDOMS population (initial model, 0.51; final model, 0.60). Fingolimod increased 
median time to disability health states (EDSS 4, 1.0 years; EDSS 6, 1.5 years) and SPMS 
(1.9 years) compared with DMF. Comparisons with teriflunomide also showed fingoli-
mod increased times to disability health states. ConClusions: Fingolimod is the 
only oral treatment that has demonstrated a significant effect on 6-month CDP in a 
clinical trial and our modeling approach suggests that progression to severe disability 
health states is delayed by fingolimod.
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objeCtives: To compare the efficacy of tobramycin powder for inhalation (TIP) rela-
tive to tobramycin inhalation solution containing 300 mg/5ml of tobramycin (TIS-T) 
and 300mg/4ml of tobramycin (TIS-B), aztreonam lysine inhalation solution (AZLI), 
colistimethate sodium solution (colistin) and colistin inhalation powder (colistin-
P) for cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosainfection, 
by updating a systematic literature review (SLR) and network meta-analysis (NMA) 
with recently published evidence. Methods: The updated SLR was conducted in 
Medline, Medline in Process, Embase and the Cochrane Library up to 2012. Individual 
study results were synthesized and indirectly compared with a Bayesian NMA. As 
some trials included naïve patients (previously not exposed to the treatment) in one 
arm, and previously exposed patients to the treatment in the other arm, the naïve 
and exposed arms were considered separate treatment-by-population groups in 
the network. Results: Three new trials were identified and analysed with eleven 
trials identified in the previous SLR. In naïve populations, TIP is expected to have 
similar efficacy as TIS-T, TIS-B, and AZLI (difference in % change in FEV1 predicted 
at week 4 respectively -1.97 (95% Credible Interval -11.84, 8.03), -2.38 (-12.71, 7.98), 
and 1.53 (-7.04, 10.00)). Compared to colistin-P, TIP is expected to have similar effi-
cacy, however the point estimate is in favour of TIP (11.36 (-1.75, 24.31)). In exposed 
populations, TIP is expected to have similar efficacy as TIS-T, TIS-B and colistin 
(respectively -0.78 (-7.65, 5.99), 0.01 (-10.42, 10.46), and -5.75 (-21.23, 9.89)). No data 
